The peptide handles the biochemistry of fat metabolism
EG: Supervision, Writing review & editing
We excluded 1) those with diagnoses of AF, atrial tachycardia, ventricular tachycardia, ventricular fibrillation, mechanical valve, hyperthyroidism, or mitral stenosis before or on the index date, 2) those with cardiac events (i.e., myocardial infarction, percutaneous intervention, valve/bypass surgery) in the preceding 3 months, 3) those currently receiving antiarrhythmic medications (e.g., amiodarone, dronedarone, flecainide, propafenone, or dofetilide) on the index date, 4) those who used insulin within one year prior or on the index date, and 5) those who do not have hemoglobin A1C (HbA1c) within one year prior or on the index date (eFigure 1)
Gotthardt D, Putz EM, Straka E, Kudweis P, Biaggio M, Poli V, Strobl B, Mller M, Sexl V
FDA recommended against inclusion
Patients should be counseled about symptoms of thyroid tumors, including a neck mass, dysphagia, dyspnea, or persistent hoarseness, though routine calcitonin monitoring is not recommended for surveillance in the absence of specific risk factors
